Substance use and spine density: a systematic review and meta-analysis of preclinical studies
Molecular Psychiatry,
Journal Year:
2024,
Volume and Issue:
unknown
Published: April 2, 2024
Language: Английский
Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimization
Frontiers in Psychiatry,
Journal Year:
2025,
Volume and Issue:
16
Published: April 8, 2025
Language: Английский
Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies
Cellular and Molecular Life Sciences,
Journal Year:
2025,
Volume and Issue:
82(1)
Published: Jan. 21, 2025
The
current
opioid
crisis
has
had
an
unprecedented
public
health
impact.
Approved
medications
for
use
disorder
(OUD)
exist,
yet
their
limitations
indicate
a
need
innovative
treatments.
Limited
preliminary
clinical
studies
suggest
specific
psychedelics
might
aid
OUD
treatment,
though
most
evidence
remains
observational,
with
few
controlled
trials.
This
review
aims
to
bridge
the
gap
between
preclinical
findings
and
potential
applications,
following
PRISMA-ScR
guidelines.
Searches
included
MEDLINE,
Embase,
Scopus,
Web
of
Science,
focusing
on
in
vivo
involving
opioids
animals,
excluding
pain
those
lacking
control
groups.
Forty
met
criteria,
covering
both
classic
non-classic
psychedelics.
Most
showed
that
18-methoxycoronaridine
(18-MC),
ibogaine,
noribogaine,
ketamine
could
reduce
self-administration,
alleviate
withdrawal
symptoms,
change
conditioned
place
preference.
However,
seven
(two
2,5-dimethoxy-4-methylamphetamine
(DOM),
three
one
18-MC,
ketamine)
no
improvement
over
controls.
A
methodological
quality
assessment
rated
as
having
unclear
quality.
Interestingly,
are
limited
iboga
derivatives,
which
were
effective,
but
these
agents
may
have
higher
cardiovascular
risk
than
other
under-explored
date.
strengthens
support
translational
testing
targets
OUD.
It
also
suggests
include
broader
range
beyond
derivatives
can
explore
several
ongoing
questions
field,
such
mechanism
action
behind
therapeutic
effect,
safety
profiles,
doses,
frequency
administrations
needed.
Language: Английский
Gastrodin prevents stress-induced synaptic plasticity impairment and behavioral dysfunction via cAMP/PKA/CREB signaling pathway
Zhihuang Zhao,
No information about this author
Pei Liu,
No information about this author
Haili Zhang
No information about this author
et al.
Phytomedicine,
Journal Year:
2025,
Volume and Issue:
unknown, P. 156661 - 156661
Published: March 1, 2025
Language: Английский
Icariin rescues developmental BPA exposure induced spatial memory deficits in rats
Danyang Li,
No information about this author
Shu Ai,
No information about this author
Chengqing Huang
No information about this author
et al.
Toxicology and Applied Pharmacology,
Journal Year:
2023,
Volume and Issue:
482, P. 116776 - 116776
Published: Dec. 1, 2023
Language: Английский
Exploring Next-Generation Therapeutics: Morphic Mixtures and Specified Salts for the Treatment of Mental Disorders and CNS Modulation
ACS Medicinal Chemistry Letters,
Journal Year:
2023,
Volume and Issue:
14(9), P. 1159 - 1161
Published: Aug. 22, 2023
This
Patent
Highlight
delves
into
the
potential
of
next-generation
therapeutics
for
treating
mental
disorders
and
modulating
central
nervous
system
(CNS).
Among
serotonin
receptor
subtypes,
5-HT2A,
5-HT2C,
5-HT1A,
5-HT1B
have
shown
promise
in
CNS
disorder
treatment.
Approved
drugs
targeting
these
receptors,
such
as
antipsychotics
psychedelics,
provide
valuable
insights
their
therapeutic
effects.
However,
modulation
receptors
can
lead
to
side
effects
like
hallucinations
altered
perception.
The
development
5-HT2A
agonists
with
minimized
mood
changes
improved
benefits
is
crucial.
Furthermore,
exploring
morphic
salt
mixtures
specified
salts
offers
innovative
approaches
effectively
activity
disorders.
Language: Английский